Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Comment by Dreimer200on Dec 30, 2024 11:24am
194 Views
Post# 36380876

RE:RE:RE:RE:Treating all patients, all comers.

RE:RE:RE:RE:Treating all patients, all comers.
There has been a significant cultural shift in the matter of precision in language. I am old enough to remember the days when errors in spelling and syntax were considered a reflection of general intellectual competence. That’s no longer the case – but – in matters of importance – language does still matter.
 
It is obvious that the writer of the press release did not intend to imply that Theralase had FDA approval – but that is the clear implication of the language used. 
 
Pedantry is much despised – this post will be considered an example of it – but the broken window theory may support it. The company – in its press releases – often uses “it’s” instead of “its.” It’s a common error – but not one that would be made by anyone who passed in the grade eight class I attended. I have always thought it unwise for any company to advertise that it has no one on staff aware of the difference, and might find it prudent to hire a proofreader – even if only on an ad hoc basis.
 
<< Previous
Bullboard Posts
Next >>